These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 29892294)

  • 1. The Interleukin-20 Cytokine Family in Liver Disease.
    Caparrós E; Francés R
    Front Immunol; 2018; 9():1155. PubMed ID: 29892294
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatoprotective and anti-inflammatory cytokines in alcoholic liver disease.
    Gao B
    J Gastroenterol Hepatol; 2012 Mar; 27 Suppl 2(Suppl 2):89-93. PubMed ID: 22320924
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic strategies for alcoholic liver disease: Focusing on inflammation and fibrosis (Review).
    Kawaratani H; Moriya K; Namisaki T; Uejima M; Kitade M; Takeda K; Okura Y; Kaji K; Takaya H; Nishimura N; Sato S; Sawada Y; Seki K; Kubo T; Mitoro A; Yamao J; Yoshiji H
    Int J Mol Med; 2017 Aug; 40(2):263-270. PubMed ID: 28627645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of Interleukin-22 in chronic liver injury.
    Carmo RF; Cavalcanti MSM; Moura P
    Cytokine; 2017 Oct; 98():107-114. PubMed ID: 27816383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cellular and cytokine-mediated mechanisms of inflammation and its modulation in immune-mediated liver injury.
    Tiegs G
    Z Gastroenterol; 2007 Jan; 45(1):63-70. PubMed ID: 17236122
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging Role of Interleukins for the Assessment and Treatment of Liver Diseases.
    Ali AL; Nailwal NP; Doshi GM
    Endocr Metab Immune Disord Drug Targets; 2022; 22(4):371-382. PubMed ID: 34819013
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alcohol, microbiome, life style influence alcohol and non-alcoholic organ damage.
    Neuman MG; French SW; Zakhari S; Malnick S; Seitz HK; Cohen LB; Salaspuro M; Voinea-Griffin A; Barasch A; Kirpich IA; Thomes PG; Schrum LW; Donohue TM; Kharbanda KK; Cruz M; Opris M
    Exp Mol Pathol; 2017 Feb; 102(1):162-180. PubMed ID: 28077318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Decoding cell death signals in liver inflammation.
    Brenner C; Galluzzi L; Kepp O; Kroemer G
    J Hepatol; 2013 Sep; 59(3):583-94. PubMed ID: 23567086
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interleukin-6: A promising cytokine to support liver regeneration and adaptive immunity in liver pathologies.
    Naseem S; Hussain T; Manzoor S
    Cytokine Growth Factor Rev; 2018 Feb; 39():36-45. PubMed ID: 29361380
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunopathobiology and therapeutic targets related to cytokines in liver diseases.
    He Y; Hwang S; Ahmed YA; Feng D; Li N; Ribeiro M; Lafdil F; Kisseleva T; Szabo G; Gao B
    Cell Mol Immunol; 2021 Jan; 18(1):18-37. PubMed ID: 33203939
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Hepatocellular damage and inflammation in various forms of alcoholic liver disease].
    Rodina AS; Shubina ME; Kurbatova IV; Topchieva LV; Dudanova OP
    Ter Arkh; 2021 Jan; 93(1):15-19. PubMed ID: 33720620
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent insights of the role and signalling pathways of interleukin-34 in liver diseases.
    Al-Shaebi F; Wenzhang L; Hezam K; Almezgagi M; Wei L
    Int Immunopharmacol; 2020 Dec; 89(Pt B):107023. PubMed ID: 33129098
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interleukins in chronic liver disease: lessons learned from experimental mouse models.
    Hammerich L; Tacke F
    Clin Exp Gastroenterol; 2014; 7():297-306. PubMed ID: 25214799
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Cytokine mediators in acute inflammation and chronic course of viral hepatitis].
    Missale G; Ferrari C; Fiaccadori F
    Ann Ital Med Int; 1995; 10(1):14-8. PubMed ID: 7727201
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interleukin 22 in Liver Injury, Inflammation and Cancer.
    Wu Y; Min J; Ge C; Shu J; Tian D; Yuan Y; Zhou D
    Int J Biol Sci; 2020; 16(13):2405-2413. PubMed ID: 32760208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Excessive bile acid activated NF-kappa B and promoted the development of alcoholic steatohepatitis in farnesoid X receptor deficient mice.
    Wu WB; Chen YY; Zhu B; Peng XM; Zhang SW; Zhou ML
    Biochimie; 2015 Aug; 115():86-92. PubMed ID: 26025474
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytokines in alcoholic liver disease.
    An L; Wang X; Cederbaum AI
    Arch Toxicol; 2012 Sep; 86(9):1337-48. PubMed ID: 22367091
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interleukins in liver disease treatment.
    Yang M; Zhang CY
    World J Hepatol; 2024 Feb; 16(2):140-145. PubMed ID: 38495285
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HCV-induced regulatory alterations of IL-1β, IL-6, TNF-α, and IFN-ϒ operative, leading liver en-route to non-alcoholic steatohepatitis.
    Nawaz R; Zahid S; Idrees M; Rafique S; Shahid M; Ahad A; Amin I; Almas I; Afzal S
    Inflamm Res; 2017 Jun; 66(6):477-486. PubMed ID: 28285394
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interleukin-35: An emerging player in the progression of liver diseases.
    Zhao N; Liu X; Guo H; Zhao X; Qiu Y; Wang W
    Clin Res Hepatol Gastroenterol; 2021 Jan; 45(1):101518. PubMed ID: 33387857
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.